Advertisement
COO vs GNGBY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COO is a StrongBuy and GNGBY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COO’s FA Score shows that 0 FA rating(s) are green whileGNGBY’s FA Score has 2 green FA rating(s).
- COO’s FA Score: 0 green, 5 red.
- GNGBY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COO’s TA Score shows that 5 TA indicator(s) are bullish while GNGBY’s TA Score has 2 bullish TA indicator(s).
- COO’s TA Score: 5 bullish, 4 bearish.
- GNGBY’s TA Score: 2 bullish, 6 bearish.
Price Growth
COO (@Pharmaceuticals: Other) experienced а -0.49% price change this week, while GNGBY (@Medical/Nursing Services) price change was -1.41% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -3.35%. For the same industry, the average monthly price growth was -3.57%, and the average quarterly price growth was +7.30%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.09%. For the same industry, the average monthly price growth was +2.86%, and the average quarterly price growth was +9.05%.
Reported Earning Dates
COO is expected to report earnings on Dec 04, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (-3.35% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-2.09% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| COO | GNGBY | COO / GNGBY | |
| Capitalization | 13.3B | 6.12B | 217% |
| EBITDA | 1.09B | 5.51B | 20% |
| Gain YTD | -27.238 | 46.087 | -59% |
| P/E Ratio | 32.79 | 36.02 | 91% |
| Revenue | 4.05B | 35.5B | 11% |
| Total Cash | 125M | 1.95B | 6% |
| Total Debt | 2.48B | 11.2B | 22% |
COO | GNGBY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 68 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | 16 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 91 | |
SMR RATING 1..100 | 85 | 85 | |
PRICE GROWTH RATING 1..100 | 64 | 48 | |
P/E GROWTH RATING 1..100 | 92 | 14 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GNGBY's Valuation (16) in the null industry is somewhat better than the same rating for COO (77) in the Medical Specialties industry. This means that GNGBY’s stock grew somewhat faster than COO’s over the last 12 months.
GNGBY's Profit vs Risk Rating (91) in the null industry is in the same range as COO (100) in the Medical Specialties industry. This means that GNGBY’s stock grew similarly to COO’s over the last 12 months.
GNGBY's SMR Rating (85) in the null industry is in the same range as COO (85) in the Medical Specialties industry. This means that GNGBY’s stock grew similarly to COO’s over the last 12 months.
GNGBY's Price Growth Rating (48) in the null industry is in the same range as COO (64) in the Medical Specialties industry. This means that GNGBY’s stock grew similarly to COO’s over the last 12 months.
GNGBY's P/E Growth Rating (14) in the null industry is significantly better than the same rating for COO (92) in the Medical Specialties industry. This means that GNGBY’s stock grew significantly faster than COO’s over the last 12 months.
| COO | GNGBY | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 66% | 3 days ago 64% |
| Stochastic ODDS (%) | 3 days ago 58% | 3 days ago 47% |
| Momentum ODDS (%) | 3 days ago 63% | 3 days ago 63% |
| MACD ODDS (%) | 3 days ago 70% | 3 days ago 51% |
| TrendWeek ODDS (%) | 3 days ago 57% | 3 days ago 57% |
| TrendMonth ODDS (%) | 3 days ago 60% | 3 days ago 69% |
| Advances ODDS (%) | 8 days ago 59% | 4 days ago 67% |
| Declines ODDS (%) | 4 days ago 60% | 8 days ago 57% |
| BollingerBands ODDS (%) | 3 days ago 71% | 3 days ago 46% |
| Aroon ODDS (%) | N/A | 3 days ago 65% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RBUF | 28.64 | 0.01 | +0.03% |
| Innovator U.S. Small Cp 10 Buf ETF - Qt | |||
| SNPV | 34.82 | N/A | N/A |
| Xtrackers S&P 500 Value Scrd & Scrn ETF | |||
| PHB | 18.53 | -0.05 | -0.27% |
| Invesco Fundamental Hi Yld® Corp Bd ETF | |||
| JMEE | 62.82 | -0.49 | -0.77% |
| JPMorgan Small & Mid Cap Enh Eq ETF | |||
| ELD | 28.58 | -0.25 | -0.87% |
| WisdomTree Emerging Markets Lcl Dbt ETF | |||
COO and
Correlation & Price change
A.I.dvisor indicates that over the last year, COO has been loosely correlated with ALC. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then ALC could also see price increases.
GNGBY and
Correlation & Price change
A.I.dvisor tells us that GNGBY and QDEL have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GNGBY and QDEL's prices will move in lockstep.
| Ticker / NAME | Correlation To GNGBY | 1D Price Change % | ||
|---|---|---|---|---|
| GNGBY | 100% | N/A | ||
| QDEL - GNGBY | 31% Poorly correlated | -0.60% | ||
| ESLOY - GNGBY | 28% Poorly correlated | N/A | ||
| SAUHY - GNGBY | 25% Poorly correlated | N/A | ||
| COO - GNGBY | 25% Poorly correlated | -2.14% | ||
| SSMXY - GNGBY | 24% Poorly correlated | N/A | ||
More | ||||